Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus.
Journal: 2006/September - Heart
ISSN: 1468-201X
Relations:
Content
Citations
(7)
References
(5)
Diseases
(1)
Drugs
(1)
Chemicals
(2)
Organisms
(1)
Processes
(1)
Anatomy
(1)
Similar articles
Articles by the same authors
Discussion board
Heart 92(9): 1335-1337

Clopidogrel reduces platelet–leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus

S A Harding, Department of Cardiology, Wellington Hospital, Wellington, New Zealand
J Sarma, J N Din, P M Maciocia, D E Newby, K A A Fox, Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK
Correspondence to: Dr Scott Harding
Department of Cardiology, Wellington Hospital, Private Bag 7902, Wellington, New Zealand; scott.harding@ccdhb.org.nz
S A Harding, Department of Cardiology, Wellington Hospital, Wellington, New ZealandJ Sarma, J N Din, P M Maciocia, D E Newby, K A A Fox, Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UKCorrespondence to: Dr Scott Harding
Department of Cardiology, Wellington Hospital, Private Bag 7902, Wellington, New Zealand; scott.harding@ccdhb.org.nz
Accepted 2006 Mar 3.

Patients with diabetes mellitus have an increased risk of developing atherosclerosis and its sequelae. Atherosclerosis is an inflammatory disease involving multiple interactions between platelets, leucocytes and endothelial cells.1 Clopidogrel, a specific antagonist of the ADP P2Y12 receptor, inhibits both platelet activation and aggregation induced by ADP.2 Although clopidogrel has well‐documented antithrombotic actions, its potential anti‐inflammatory effects have been little investigated. We examined whether specific platelet inhibition with clopidogrel would reduce systemic inflammatory markers and specifically platelet, monocyte and endothelial activation in patients with type 2 diabetes mellitus.

Abbreviations

FITC - fluorescein isothiocyanate

PBS - phosphate‐buffered saline

PE - phycoerythrin

RANTES - regulated on activation normal T cell expressed presumed secreted

sCD40L - soluble CD40 ligand

Abbreviations

Footnotes

Grant support: Drs Harding and Din were supported by grants from the British Heart Foundation (PG/2001/068; PG/03/009)

Competing interests: Professor Fox has received grant support for the Global Registry of Acute Coronary Events (GRACE) from Sanofi‐Aventis. All other authors have no conflict of interest to declare

Footnotes

References

  • 1. Huo Y, Ley K FRole of platelets in the development of atherosclerosis. Trends Cardiovasc Med 20041418–22. [[PubMed][Google Scholar]
  • 2. Solet D, Zacharski L, Plehn JThe role of adenosine 5′‐diphosphate receptor blockade in patients with cardiovascular disease. Am J Med 200111145–53. [[PubMed][Google Scholar]
  • 3. Appay V, Rowland‐Jones S LRANTES: a versatile and controversial chemokine. Trends Immunol 20012283–87. [[PubMed][Google Scholar]
  • 4. Xiao Z, Theroux PClopidogrel inhibits platelet‐leukocyte interactions and thrombin receptor agonist peptide‐induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004431982–1988. [[PubMed][Google Scholar]
  • 5. Quinn M J, Bhatt D L, Zidar F. et al Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 200493679–684. [[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.